Osmosis Investment Management UK Ltd Makes New $7.26 Million Investment in Axon Enterprise, Inc $AXON

Osmosis Investment Management UK Ltd bought a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 12,950 shares of the biotechnology company’s stock, valued at approximately $7,260,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Axon Enterprise by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after acquiring an additional 53,060 shares in the last quarter. BlackRock Inc. raised its position in shares of Axon Enterprise by 4.3% in the 2nd quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock worth $4,672,432,000 after acquiring an additional 345,365 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after acquiring an additional 35,544 shares in the last quarter. Sands Capital Management LLC lifted its stake in shares of Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after purchasing an additional 167,095 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Axon Enterprise by 326.9% in the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after purchasing an additional 1,179,038 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insiders Place Their Bets

In other news, President Joshua Isner sold 13,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the transaction, the president owned 169,125 shares in the company, valued at approximately $82,609,106.25. This trade represents a 7.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jeri Williams sold 629 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $469.64, for a total transaction of $295,403.56. Following the completion of the sale, the director directly owned 1,141 shares of the company’s stock, valued at $535,859.24. The trade was a 35.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 66,989 shares of company stock worth $35,216,932. 4.20% of the stock is owned by company insiders.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $627.75 on Monday. The stock has a 50-day moving average price of $543.11 and a 200 day moving average price of $476.99. The stock has a market capitalization of $51.00 billion, a P/E ratio of 260.48, a P/E/G ratio of 10.19 and a beta of 1.39. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $794.29. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, topping the consensus estimate of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The business had revenue of $904.39 million for the quarter, compared to analysts’ expectations of $876.42 million. During the same quarter in the previous year, the company earned $2.12 EPS. The business’s quarterly revenue was up 35.3% compared to the same quarter last year. Equities research analysts forecast that Axon Enterprise, Inc will post 2.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. UBS Group boosted their target price on shares of Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Citizens Jmp reiterated a “market outperform” rating and set a $700.00 price target on shares of Axon Enterprise in a report on Thursday, June 25th. Piper Sandler boosted their price objective on shares of Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Axon Enterprise in a research note on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $730.92.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.